Meeting
2017 ASCO Annual Meeting
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).
Authors
Bo Zhai
Department of Interventional Oncology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Bo Zhai , Donghua Shi , Huiping Gao , Xingxing Qi , Hua Jiang , Yuan Zhang , Jiachang Chi , Huaying Ruan , Huamao Wang , Qinhua Cindy Ru , Zonghai Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT02395250
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3049)
DOI
10.1200/JCO.2017.35.15_suppl.3049
Abstract #
3049
Poster Bd #
144
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.
First Author: Zhongwei Zhao
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
First Author: Changqing Xie
Poster
2022 ASCO Annual Meeting
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
First Author: Sarah Marie Larson
Poster
2019 ASCO Annual Meeting
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
First Author: Hui Liu